Patent intelligence · US
US 12318487
Solid tablet dosage form of ridinilazole
Solid tablet dosage form of ridinilazole
Patent details — US 12318487
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 3, 2025
- Expiration
- May 29, 2045
- Applicant
- SUMMIT (OXFORD) LIMITED
- Claims
- 39
- CPC classes
- A61K, A61K31/4439, A61K31/444, A61K47/26
Quick answer
US 12318487 (Solid tablet dosage form of ridinilazole) is held by SUMMIT (OXFORD) LIMITED. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUMMIT (OXFORD) LIMITED
- Grant date
- Expiration
- Claims
- 39
- CPC classes
- A61K, A61K31/4439, A61K31/444, A61K47/26, A61K9/2018, A61K9/2054
More from SUMMIT (OXFORD) LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 11344575
Vascular calcification prevention and treatment
granted -
US 11007171
Treatment and prevention of joint disorders
granted -
US 9763925
Antibacterial compounds
granted -
US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted -
US 9314456
Antibacterial compounds
granted -
US 9278091
Compounds for the treatment of Clostridium difficile associated disease
granted -
US 8987308
Compounds for the treatment of Clostridium difficile-associated disease
granted
Frequently asked questions
What is US patent 12318487?
US 12318487 (Solid tablet dosage form of ridinilazole) is held by SUMMIT (OXFORD) LIMITED. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12318487?
SUMMIT (OXFORD) LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 12318487 expire?
Our index shows an expiration date of May 29, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.